Exenatide (revision 2)
Old revision·16:15, 28 Sep 2024·SecretagogueSol
This is an old revision of this page, as it stood at 16:15, 28 Sep 2024, saved by SecretagogueSol with the summary expand §Origin and sequence. It may differ substantially from the current revision, and any error it contains may since have been corrected.
| Exenatide | |
|---|---|
| INN | exenatide |
| Class | GLP-1 receptor agonist |
| Origin | Synthetic exendin-4 |
| First approval | 2005 |
| Compound infobox · conventions | |
Exenatide is a synthetic version of exendin-4, a 39-residue peptide isolated from the venom of the Gila monster, Heloderma suspectum. It shares approximately 53% sequence identity with human Glucagon-like peptide-1 and is a full agonist at the GLP-1 receptor. Approved in 2005, it was the first GLP-1 receptor agonist to reach the market.[1]
Its therapeutic relevance rests on an accident of sequence: exendin-4 carries glycine rather than alanine at position 2, so DPP-4 does not cleave it. No engineering was required to obtain protease resistance — the peptide is naturally resistant, and this is why a venom peptide became a diabetes drug.[1]
References
Categories: